Help me fill in the blanks of the practice of ED Critical Care. In this podcast, we discuss all things related to the crashing, critically ill patient in the Emergency Department. Find the show notes at emcrit.org.
…
continue reading
Content provided by Audioboom and OncLive® On Air. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and OncLive® On Air or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
S14 Ep1: Obe-Cel Data Are Poised to Refine and Expand the ALL Treatment Paradigm: With Aaron Logan, MD, PhD; and Bijal Shah, MD, MS
MP3•Episode home
Manage episode 502625258 series 2395115
Content provided by Audioboom and OncLive® On Air. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and OncLive® On Air or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In today’s episode, supported by Autolus, we spoke with Aaron Logan, MD, PhD, and Bijal Shah, MD, MS, about the evolving use of obecabtagene autoleucel (obe-cel; Aucatzyl) in the relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treatment paradigm. Dr Logan is an associate professor of clinical medicine in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF) School of Medicine, as well as a member of the UCSF Helen Diller Family Comprehensive Cancer Center. Dr Shah is an associate member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.
In our conversation, Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm, how the use of this agent might expand going forward, and what the future looks like for the broader CAR T-cell therapy development field in ALL.
In our conversation, Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm, how the use of this agent might expand going forward, and what the future looks like for the broader CAR T-cell therapy development field in ALL.
669 episodes
MP3•Episode home
Manage episode 502625258 series 2395115
Content provided by Audioboom and OncLive® On Air. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and OncLive® On Air or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In today’s episode, supported by Autolus, we spoke with Aaron Logan, MD, PhD, and Bijal Shah, MD, MS, about the evolving use of obecabtagene autoleucel (obe-cel; Aucatzyl) in the relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treatment paradigm. Dr Logan is an associate professor of clinical medicine in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF) School of Medicine, as well as a member of the UCSF Helen Diller Family Comprehensive Cancer Center. Dr Shah is an associate member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.
In our conversation, Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm, how the use of this agent might expand going forward, and what the future looks like for the broader CAR T-cell therapy development field in ALL.
In our conversation, Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm, how the use of this agent might expand going forward, and what the future looks like for the broader CAR T-cell therapy development field in ALL.
669 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.